Japan And London

OSAKA, Japan and LONDON, October 21, 2011 - European Medicines Agency recognizes that Takeda's pioglitazone-containing medicines remain a valid treatment option for appropriate type 2 diabetes patients Takeda Pharmaceutical Company Limited ("Takeda") announced today that at the request of the European Commission (EC), the European Medicines Agency (EMA)'s Committee for Medical Products for Human Use (CHMP) has clarified the label changes for pioglitazone-containing medicines recommended in July of this year.

OSAKA, Japan and LONDON, February 1 - Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Pharmaceuticals Europe Limited ("TPEU"), its wholly owned subsidiary for oversight of pan-European sales and marketing, jointly announced today that Mepact(R) (mifamurtide)(1), the first new treatment in 20 years to improve survival in patients with osteosarcoma (malignant bone cancer)(2), is now commercially available in the European Union - via a paid named-patient programme in countries where it is not initially reimbursed.* To view the Multimedia News Release, please click: multivu.prnewswire.com/mnr/prne/takeda/40775 Osteosarcoma is a rare and often fatal disease, with approximately 1,200 new cases diagnosed in Europe each year; primarily children and young adults(3).The standard treatment for osteosarcoma is surgical removal of the tumour (resection) with combination chemotherapy before and after surgery.